Reviewer’s report

Title: A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand

Version: 0 Date: 20 May 2018

Reviewer: Sajjad Mahmood

Reviewer's report:

Please include all comments for the authors in this box rather than uploading your report as an attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting materials or other aspects of your report which cannot be included in a text format.

Please overwrite this text when adding your comments to the authors.

This is a real world effectiveness study.

For such a study six month follow-up is insufficient to add value to existing literature related to the drugs and disease indications studied and reported.

12 month results would be worth reporting and publishing. There is reference to a "main study" which presumably has a longer follow-up duration.

The study refers to two different treatment arms. This is not adequately explained throughout the paper. Does this reflect patients receiving a loading dose or not receiving a loading dose? Did this reflect differences in clinical practice, disease indication or reimbursement? Depending on the reason different effects would be expected on the overall study outcomes.

There appear to be disparate methods of data collection and medical records standard between the centres.

With such a variety of disease indications and rage of visions a full cohort analysis of BCVA is not meaningful. The paper would be better analysing all disease indications throughout.

One of the main aims of the paper to compare IVB and IVR is not possible to do meaningfully with the low sample size of IVR ini relation to IVB.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Unable to assess

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

   Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

Consulting / speaker fees and travel grants from Novartis manufacturer of ranibizumab

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal